5′-nucleotidase ecto (CD73 (also NT5E))

5′-nucleotidase ecto (CD73, NT5E) is a glycosylphosphatidylinositol (GPI)-anchored ectoenzyme located primarily on the plasma membrane of various cell types[1][2][4][7]. Its primary enzymatic function is to hydrolyze extracellular adenosine monophosphate (AMP) to adenosine, thereby regulating extracellular nucleotide and nucleoside levels and serving as a crucial regulator of purinergic signaling. Beyond its enzymatic activity, CD73 acts as an adhesion molecule and an immune checkpoint—mediating cell-cell interactions, suppressing immune responses, and contributing to tumor immune escape by generating immunosuppressive adenosine in the tumor microenvironment[1][2][4]. Aberrant expression and alternative splicing of NT5E are implicated in a range of diseases, particularly in the context of cancer progression, fibrosis, and immune modulation[8][6][9]. CD73 is currently a therapeutic target in oncology and immunology due to its roles in tumor immunity and inflammation, and it is under investigation as both a prognostic/predictive biomarker and a drug target[9][6]. Note: The query name "NT5E mRNA" actually refers to the mRNA transcript encoding CD73, but in drug discovery and molecular targeting, the protein product (CD73/NT5E) is the relevant therapeutic target. There is no therapeutic targeting of "NT5E mRNA" per se unless specifically referring to mRNA-level interventions such as siRNA or antisense oligonucleotides; standard drug discovery focuses on the encoded protein. The information above refers to the canonical protein target[1][2][7].

Other names

ecto-5′-nucleotidaseCD73NT5Ecluster of differentiation 73

Inhibition of adenosine production by blocking hydrolysis of AMP; Modulation of purinergic (adenosine) signaling pathways; Augmentation of anti-tumor immune response by blocking immune checkpoint function